“…As a chronic condition, osteoporosis necessitates long-term management, but patient adherence to long-term drug regimens remains unsatisfactory [ 4 , 5 ]. Additionally, certain therapies have notable adverse effects, ranging from musculoskeletal discomfort to rare but severe complications, such as medication-related osteonecrosis of the jaw (MRONJ) and atypical femoral fractures (AFFs), when used for prolonged use [ 6 , 7 ]. Evaluating the strengths, limitations, and long-term benefit-to-risk ratios of each medication is crucial, as is a specific focus on advancements in long-term and sequential treatment strategies.…”